The Chinese-German Journal of Clinical Oncology

, Volume 8, Issue 9, pp 526–530 | Cite as

Efficacy and safety profiles of cetuximab in Chinese patients with colorectal cancer

  • Liangping XiaEmail author
  • Guifang Guo
  • Huijuan Qiu
  • Bei Zhang
  • Feifei Zhou



The aim of this study was to investigate the efficacy and safety profiles of cetuximab, the commonly used monoclonal antibody of epidermal growth factor receptor, based on Chinese patients with colorectal cancer.


All the papers studied on Chinese patients with gastrointestinal cancer treated by cetuximab and found in both databases of Chinese journal database for fulltext and PubMed were collected. The commonly used efficacy index such as disease control rate (CR + PR + SD) and response rate (CR + PR) were analyzed, and the cetuximab related side effects such acne-like rash and nail change and hypersensitivity were analyzed too.


(1) There were 10 original papers contained total 152 patients with gastrointestinal cancer who were the candidates to analyze the safety profiles, and contained 130 patients with colorectal cancer who were candidates to analyze the efficacy. (2) The disease control rate and response rate in the whole group was 73.5% (95% CI: 65.5%–81.5%) and 29.1% (95% CI: 20.9%–37.3%), respectively; In first-line setting group they were 70.0% (95% CI: 55%–85%) and 41.7% (95% CI: 25.6%–57.8%), respectively; In non-first line setting group they were 71.6% (95% CI: 61.8%–81.4%) and 23.5% (95% CI: 14.3%–32.7%), respectively. The disease control rate between the two line-setting groups was insignificant, but the response rate between the two line-setting groups was significant (P = 0.045). (3) The incidence of acne-like rash was 72.0% (95% CI: 64.8%–79.2%), the degree I–II and degree III–IV account for 56.0% (95% CI: 48.1%–63.9%) and 16.0% (95% CI: 10.1%–21.9%), respectively. No treatment related death, and the hypersensitivity was under control.


This study is the first study to summarize the data of Chinese patients with colorectal cancer treated by cetuximab-contained regimen, it showed that the monoclonal antibody was effective and safe for Chinese patients as the West patients with colorectal cancer.

Key words

Chinese patient colorectal cancer cetuximab efficacy side effects 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 2009, 27:663–671.PubMedCrossRefGoogle Scholar
  2. 2.
    Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol, 2008, 26:2311–2319.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 2004, 351: 337–345.PubMedCrossRefGoogle Scholar
  4. 4.
    Vincenzi B, Santini D, Rabitti C, et al. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. Br J Cancer, 2006, 94: 792–797.PubMedCrossRefGoogle Scholar
  5. 5.
    Borghaei H, Langer CJ, Millenson M, et al. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol, 2008, 3: 1286–1292.PubMedGoogle Scholar
  6. 6.
    Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol, 2007, 25: 5777–5784.PubMedCrossRefGoogle Scholar
  7. 7.
    Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 2005, 23:3568–3576.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang WF, Liu LK, Liu YQ. Clinical usefulness of cetuximab in combination with chemotherapy in the treatment of gastrointestinal cancer. Chin J Mod Drug Appl (Chinese), 2008, 12: 18–20.Google Scholar
  9. 9.
    Ye HY, Zhang YH, Chen JQ, et al. Effects of cetuximab plus chemotherapy in first-line treatment of advanced colorectal cancer. Chin Oncol (Chinese), 2008, 18: 704–706.Google Scholar
  10. 10.
    Jin X, Bai Y, Yu JL, et al. The clinical observation of cetuximab in combination with chemotherapy in metastatic colorectal cancer patients. J Basic Clin Oncol (Chinese), 2008, 21: 682–882.Google Scholar
  11. 11.
    Zhang XT, Shen L, Zhang XD, et al. Cetuximab in combinationn with chemotherapy for patients with gastrointestinal cancer. Chin J Oncol (Chinese), 2008, 30: 385–388.Google Scholar
  12. 12.
    Wang M, Wang W, Li YM, et al. Cetuximab plus mIFL in treatment of oxaliplatin-resistant metastatic colorectal cancer: efficacy and toxicity. Chin J Cancer Biother (Chinese), 2008, 15: 371–571.Google Scholar
  13. 13.
    Lin RB, Guo ZQ, Chen YG, et al. Cetuximab in combination with irinotecan to treat chemotherapy-resistant advanced colorectal cancer. Chin Oncol (Chinese), 2008, 18: 79–80.Google Scholar
  14. 14.
    Qian J, Qin SK, Cao MR, et al. The clinical observation of cetuximab plus irinotecan in the treatment of refractory metastatic colorectal cancer. Chin Oncol (Chinese), 2007, 17: 92–94.Google Scholar
  15. 15.
    Huang JZ, Dong MX, Yu SK. Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab. Chin Pract Med (Chinese), 2007, 2: 9–11.Google Scholar
  16. 16.
    Wang RZ, Chen ZQ, Wu PE, et al. Cetuximab plus chemotherapy and/or radiotherapy in the treatment of refractory metastatic cancer. Chin Oncol (Chinese), 2007, 17: 653–656.Google Scholar
  17. 17.
    Hu WM, Deng XF, Lu WQ, et al. Clinical observation of cetuximab plus irinotecan in the treatment of advanced colorectal cancer. J Pract Med (Chinese), 2007, 23: 2591–2592.Google Scholar
  18. 18.
    Jonker DJ, O’Callaghan CJ, Karapetis CS, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med, 2007, 357: 2040–2048.PubMedCrossRefGoogle Scholar
  19. 19.
    Dai Q, Cai QY, Shu XO, et al. Synergistic effects of STK15 gene polymorphisms and endogenous estrogen exposure in the risk of breast cancer. Cancer Epidemiol Biomarkers Prev, 2004, 13: 2065–2070.PubMedGoogle Scholar
  20. 20.
    Chang A, Parikh P, Thongprasert S, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, 2006, 1: 847–855.PubMedCrossRefGoogle Scholar
  21. 21.
    Haller DJ, Cassidy J, Clarke S, et al. Tolerability of fluoropyrimidines appears to differ by region. J Clin Oncol, 2006, 24(June 20 Suppl): 3514.Google Scholar
  22. 22.
    Souglakos J, Kalykaki A, Vamvakas L, et al. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Ann Oncol, 2007, 18: 305–310.PubMedCrossRefGoogle Scholar
  23. 23.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359: 378–390.PubMedCrossRefGoogle Scholar
  24. 24.
    Koo DH, Lee JL, Kim TW, et al. A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer. J Korean Med Sci, 2007, 22, S98–S103.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2009

Authors and Affiliations

  • Liangping Xia
    • 1
    Email author
  • Guifang Guo
    • 1
  • Huijuan Qiu
    • 1
  • Bei Zhang
    • 1
  • Feifei Zhou
    • 1
  1. 1.VIP Region, Cancer CenterSun Yat-sen University, National Laboratory of Oncology in South ChinaGuangzhouChina

Personalised recommendations